Official UK procurement notice
Herpes zoster (shingles) vaccine (recombinant, adjuvanted)
Authority: Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency (Central government)
What is being bought
Published requirement descriptionContract for the supply of herpes zoster, inactivated vaccine
CPV: Vaccines
The lotProcurement structure
single lot · no lot value publishedLot #1The provision of a vaccine to protect against Shingles, to be used in the national…Awarded
The provision of a vaccine to protect against Shingles, to be used in the national immunisation programme. Deliveries will be required over the initial term of 3 years and the contract has the option to be extended for up to an additional 12 months. Additional information: Value - The value has been withheld so as not to prejudice the legitimate commercial interest of the supplier
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 14 Feb 2023, 12:03 GMT
- Last source update
- 14 Feb 2023, 12:03 GMT
- Authority reference
CM/PHV/23/25156- FTS notice number
2023/S 000-004476- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-03a576Find a Tender
- Why no open competition
The works, supplies or services can be provided only by a particular economic operator due to protection of exclusive rights, including intellectual property rights
- Published justification
The Contracting Authority used the negotiated procedure without prior publication under Regulation 32(2)(b)(iii) – to protect exclusive rights - to purchase a quantity of Shingrix. The JCVI has made a recommendation that Shingrix exclusively be used for the national shingles vaccination programme due to the superiority of the vaccine and DHSC is obliged by law to adopt that recommendation, and the Supplier has global exclusive legal rights to manufacture and distribute Shingrix.
Publisher note: The contract(s) is for the benefit of the contracting authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments and their executive agencies or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting products delivered against the contract(s) may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories to undertake their respective vaccination programmes.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| GLAXOSMITHKLINE UK LIMITED | £1 † | — | Awarded |
Contracts
Contract 004476-2023-1 · GLAXOSMITHKLINE UK LIMITED
- Signed
- 13 Feb 2023
- Value
- £1
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids | — | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- The High CourtReview body
Bidders & participating suppliers
1 commercial party on the notice- GLAXOSMITHKLINE UK LIMITED - VaccinesAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.